Takeda To Assume Development Costs Of Synthetic ESA Product Hematide
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a $535 mil. deal, the Japanese firm will collaborate with Affymex on U.S. development of Hematide and solely pursue global development.
You may also be interested in...
Affymax Lays Out Hematide Phase III Development Plan For Anemia
FDA allows firm to compare the novel artificial peptide-based ESA head-to-head with currently marketed recombinant products, a move that may bode well for EPOs in upcoming Cardio Renal panel review.
Affymax Lays Out Hematide Phase III Development Plan For Anemia
FDA allows firm to compare the novel artificial peptide-based ESA head-to-head with currently marketed recombinant products, a move that may bode well for EPOs in upcoming Cardio Renal panel review.
Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.